Met Life Investment Management, LLC Relmada Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Jun 14, 2023
BUY
$18.3 - $37.02 $257,865 - $521,648
14,091 New
14,091 $521,000
Q2 2022

Jun 20, 2023
BUY
$16.5 - $30.34 $232,501 - $427,520
14,091 New
14,091 $267,000
Q1 2022

May 10, 2024
BUY
$16.72 - $26.99 $235,601 - $380,316
14,091 New
14,091 $380,000
Q1 2022

Jun 20, 2023
BUY
$16.72 - $26.99 $235,601 - $380,316
14,091 New
14,091 $380,000
Q1 2022

Mar 22, 2023
BUY
$16.72 - $26.99 $122,674 - $198,025
7,337 Added 108.63%
14,091 $380,000
Q1 2022

May 12, 2022
BUY
$16.72 - $26.99 $122,674 - $198,025
7,337 Added 108.63%
14,091 $380,000
Q4 2021

Jun 21, 2023
BUY
$16.93 - $26.82 $114,345 - $181,142
6,754 New
6,754 $152,000
Q3 2021

Jun 21, 2023
BUY
$21.86 - $34.77 $147,642 - $234,836
6,754 New
6,754 $177,000
Q2 2021

Jun 21, 2023
BUY
$29.55 - $39.15 $199,580 - $264,419
6,754 New
6,754 $216,000
Q1 2021

May 17, 2024
BUY
$31.52 - $39.28 $212,886 - $265,297
6,754 New
6,754 $237,000
Q1 2021

Jun 26, 2023
BUY
$31.52 - $39.28 $212,886 - $265,297
6,754 New
6,754 $238 Million
Q4 2020

Jun 22, 2023
BUY
$29.88 - $39.8 $201,809 - $268,809
6,754 New
6,754 $216,000
Q3 2020

Jun 26, 2023
BUY
$34.42 - $43.78 $232,472 - $295,690
6,754 New
6,754 $254,000
Q2 2020

May 24, 2024
BUY
$31.59 - $49.98 $213,358 - $337,564
6,754 New
6,754 $302 Million
Q2 2020

Jun 26, 2023
BUY
$31.59 - $49.98 $213,358 - $337,564
6,754 New
6,754 $302,000
Q2 2020

Mar 22, 2023
BUY
$31.59 - $49.98 $213,358 - $337,564
6,754 New
6,754 $302,000
Q2 2020

Aug 14, 2020
BUY
$31.59 - $49.98 $213,358 - $337,564
6,754 New
6,754 $302,000

Others Institutions Holding RLMD

# of Institutions
81
Shares Held
12.3M
Call Options Held
229K
Put Options Held
138K
View Full List

About RELMADA THERAPEUTICS, INC.

RLMD Quotes by TradingView
  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.3M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email